search
Back to results

A Study to Test Performance of Needle Placements for Neuraxial Procedures Using Tactile Imaging vs Control

Primary Purpose

Central Nervous System Infections, Pseudotumor Cerebri, Neurological Disorder

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Tactile Imaging (VerTouch)
Control (palpation)
Sponsored by
IntuiTap Medical, Inc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Central Nervous System Infections focused on measuring Diagnostic spinal puncture, Therapeutic spinal puncture, Lumbar puncture, Epidural, Neuraxial anesthesia, Blood patch, ESI

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Males and females aged 18 years and above, inclusive
  2. Subjects scheduled for one of the following procedures:

    • Diagnostic LP (collection of CSF and/or measurement of ICP to diagnose hemorrhaging or neurological infections)
    • Therapeutic LP (intrathecal injection of therapeutic agents; drainage of CSF to treat pseudotumor cerebri)
    • Planned orthopedic or obstetric procedure, such as labor/induction, cesarean section, hysterectomy, or total hip/knee replacement, with neuraxial anesthesia (injection of anesthetic into spinal and/or epidural space to reduce pain during procedure)
    • Epidural blood patch (use of autologous blood to close holes in the dura mater and relieve PDPH)
  3. Subjects having a BMI ≤42kg/m2

Exclusion Criteria:

  1. Patient does not provide informed consent
  2. Skin or soft tissue infection near the puncture site
  3. Allergy to local anesthetic
  4. Uncorrected coagulopathy
  5. Acute spinal cord trauma
  6. History of lumbar spinal surgery
  7. Prior known failed neuraxial anesthesia
  8. Diagnosed scoliosis, thoracic kyphosis, lumbar lordosis, scleroderma, or ankylosing spondylitis, or lumbar spinal stenosis
  9. Incarcerated subjects

Sites / Locations

  • Rhode Island Hospital
  • University of Texas Health Science Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Experimental Group 1: Tactile Imaging (VerTouch)

Group 2: Control (palpation)

Arm Description

VerTouch used to identify and mark, or begin placement of a needle, at an insertion site.

Palpation used to identify and mark an insertion site.

Outcomes

Primary Outcome Measures

Number of insertion attempts
Any forward movement of the needle following puncture of the skin, counted until confirmation of spinal canal access can be assessed.

Secondary Outcome Measures

Incidence of first-insertion success
A case that does not require any reinsertions, but can include any number of redirections.
Number of redirections
Any forward movement of the needle in a new direction not preceded by withdrawal from the skin, counted until confirmation of spinal canal access can be assessed.
Number of passes
Any forward movement of the needle, calculated as the sum of insertions and redirections.
Incidence of first-pass success
A case that does not require reinsertions or redirections.
Subject discomfort during landmarking
Evaluated using a 10-point Numeric Pain Rating Scale, where 1 is equivalent to no pain and 10 is equivalent to the worst possible pain.
Provider confidence with the identified insertion site
Evaluated using a 1-5 point Numeric Rating Scale where 1 is equivalent to not at all confident and 5 equivalent to completely confident.

Full Information

First Posted
March 10, 2021
Last Updated
November 23, 2022
Sponsor
IntuiTap Medical, Inc
Collaborators
ICON plc
search

1. Study Identification

Unique Protocol Identification Number
NCT04796935
Brief Title
A Study to Test Performance of Needle Placements for Neuraxial Procedures Using Tactile Imaging vs Control
Official Title
An Open-Label, Parallel, Randomized Study to Evaluate the Performance of Needle Placements for Diagnostic and Therapeutic Neuraxial Procedures, Using a Handheld Tactile Imaging-based Method Versus Palpation
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Completed
Study Start Date
April 4, 2021 (Actual)
Primary Completion Date
November 24, 2021 (Actual)
Study Completion Date
November 24, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
IntuiTap Medical, Inc
Collaborators
ICON plc

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will compare the VerTouch device to the conventional palpation technique for performing diagnostic and therapeutic neuraxial procedures.
Detailed Description
Neuraxial procedures, in which a needle is inserted into the spinal canal through a gap in the vertebrae, are performed at a rate of nearly 13 million per year in the US, across a myriad of diagnostic and therapeutic clinical scenarios. The standard of care involves manual palpation of the patient's back to detect the spinous processes (SPs) and estimate the location of the interspinous needle insertion site. While providers are trained to perform these procedures with meticulous precision and attention to detail, this technique remains highly inaccurate, often requiring multiple insertion attempts to properly place the needle. These attempts lead to patient pain and complications, such as traumatic taps and post-dural puncture (PDPH) headaches; unpredictable procedure times; and poor facility throughput. The VerTouch device uses tactile imaging to offer a non-invasive, untethered, non radiation-producing solution for visualizing spinal anatomy in order to identify an ideal location for needle placement in a neuraxial procedure. The device can be used to mark the identified site with a surgical marker, or to begin placement of a needle or introducer at that site. Study participants will be recruited in two parallel cohorts: the control (palpation) group or the tactile imaging (VerTouch) group, further stratified by procedure setting, including emergency medicine, neurology, and anesthesiology. Once an insertion site is marked with a marker or shallow placement of a needle or introducer, the procedure will continue in the usual manner for subjects in both groups.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Central Nervous System Infections, Pseudotumor Cerebri, Neurological Disorder, Cancer, Obstetric Procedure Pain, Orthopedic Procedure Pain, Post-Dural Puncture Headache
Keywords
Diagnostic spinal puncture, Therapeutic spinal puncture, Lumbar puncture, Epidural, Neuraxial anesthesia, Blood patch, ESI

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
An open-label, parallel, randomized study design
Masking
None (Open Label)
Allocation
Randomized
Enrollment
91 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Experimental Group 1: Tactile Imaging (VerTouch)
Arm Type
Experimental
Arm Description
VerTouch used to identify and mark, or begin placement of a needle, at an insertion site.
Arm Title
Group 2: Control (palpation)
Arm Type
Active Comparator
Arm Description
Palpation used to identify and mark an insertion site.
Intervention Type
Device
Intervention Name(s)
Tactile Imaging (VerTouch)
Intervention Description
VerTouch device used to identify and mark, or begin placement of a needle at an insertion site. After the device is taken off the back, the procedure will continue in the usual manner.
Intervention Type
Other
Intervention Name(s)
Control (palpation)
Intervention Description
Control, palpation used to identify and mark an insertion site.
Primary Outcome Measure Information:
Title
Number of insertion attempts
Description
Any forward movement of the needle following puncture of the skin, counted until confirmation of spinal canal access can be assessed.
Time Frame
End of procedure
Secondary Outcome Measure Information:
Title
Incidence of first-insertion success
Description
A case that does not require any reinsertions, but can include any number of redirections.
Time Frame
End of procedure
Title
Number of redirections
Description
Any forward movement of the needle in a new direction not preceded by withdrawal from the skin, counted until confirmation of spinal canal access can be assessed.
Time Frame
End of procedure
Title
Number of passes
Description
Any forward movement of the needle, calculated as the sum of insertions and redirections.
Time Frame
End of procedure
Title
Incidence of first-pass success
Description
A case that does not require reinsertions or redirections.
Time Frame
End of procedure
Title
Subject discomfort during landmarking
Description
Evaluated using a 10-point Numeric Pain Rating Scale, where 1 is equivalent to no pain and 10 is equivalent to the worst possible pain.
Time Frame
End of procedure
Title
Provider confidence with the identified insertion site
Description
Evaluated using a 1-5 point Numeric Rating Scale where 1 is equivalent to not at all confident and 5 equivalent to completely confident.
Time Frame
End of procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males and females aged 18 years and above, inclusive Subjects scheduled for one of the following procedures: Diagnostic LP (collection of CSF and/or measurement of ICP to diagnose hemorrhaging or neurological infections) Therapeutic LP (intrathecal injection of therapeutic agents; drainage of CSF to treat pseudotumor cerebri) Planned orthopedic or obstetric procedure, such as labor/induction, cesarean section, hysterectomy, or total hip/knee replacement, with neuraxial anesthesia (injection of anesthetic into spinal and/or epidural space to reduce pain during procedure) Epidural blood patch (use of autologous blood to close holes in the dura mater and relieve PDPH) Subjects having a BMI ≤42kg/m2 Exclusion Criteria: Patient does not provide informed consent Skin or soft tissue infection near the puncture site Allergy to local anesthetic Uncorrected coagulopathy Acute spinal cord trauma History of lumbar spinal surgery Prior known failed neuraxial anesthesia Diagnosed scoliosis, thoracic kyphosis, lumbar lordosis, scleroderma, or ankylosing spondylitis, or lumbar spinal stenosis Incarcerated subjects
Facility Information:
Facility Name
Rhode Island Hospital
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02903
Country
United States
Facility Name
University of Texas Health Science Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study to Test Performance of Needle Placements for Neuraxial Procedures Using Tactile Imaging vs Control

We'll reach out to this number within 24 hrs